Modality
Degrader
MOA
ALKi
Target
GIP-R
Pathway
Checkpoint
PAH
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Nov 2031
Phase 1Current
NCT03100923
2,808 pts·PAH
2019-02→2031-11·Active
NCT06952553
522 pts·PAH
2025-05→2026-10·Not yet recruiting
3,330 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-05-162mo awayEMA Filing· PAH
2026-10-167mo awayPh2 Data· PAH
2031-11-215.6y awayPh2 Data· PAH
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Active
P1/2
Not yet…
Catalysts
EMA Filing
2026-05-16 · 2mo away
PAH
Ph2 Data
2026-10-16 · 7mo away
PAH
Ph2 Data
2031-11-21 · 5.6y away
PAH
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03100923 | Phase 1/2 | PAH | Active | 2808 | CR |
| NCT06952553 | Phase 1/2 | PAH | Not yet recr... | 522 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 |